Reviewing Proteostasis Therapeutics (PTI) and Its Competitors

Proteostasis Therapeutics (NASDAQ: PTI) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Proteostasis Therapeutics to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, risk, valuation and earnings.


This table compares Proteostasis Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Proteostasis Therapeutics -712.49% -93.15% -76.61%
Proteostasis Therapeutics Competitors -6,417.56% -86.59% -37.07%

Analyst Ratings

This is a summary of recent recommendations and price targets for Proteostasis Therapeutics and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Proteostasis Therapeutics 0 0 3 0 3.00
Proteostasis Therapeutics Competitors 1134 3417 11919 240 2.67

Proteostasis Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 217.46%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.41%. Given Proteostasis Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Proteostasis Therapeutics is more favorable than its peers.

Institutional & Insider Ownership

51.8% of Proteostasis Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.4% of Proteostasis Therapeutics shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Proteostasis Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Proteostasis Therapeutics $8.38 million -$37.23 million -2.28
Proteostasis Therapeutics Competitors $290.27 million $35.99 million 54.56

Proteostasis Therapeutics’ peers have higher revenue and earnings than Proteostasis Therapeutics. Proteostasis Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply